DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloCentro de Investigaciones Inmunológicas Básicas y Aplicadas es
cic.versioninfo:eu-repo/semantics/publishedVersiones
dc.date.accessioned2017-09-19T14:37:14Z
dc.date.available2017-09-19T14:37:14Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/6168
dc.titleDMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutationsen
dc.typeArtículoes
dcterms.abstractControversy always existed on the utility of chemically induced mouse mammary carcinogenesis models as valid equivalents for the study of human breast cancer. Here, we performed whole exome and RNA sequencing on long latency mammary tumors (218 ± 27 days) induced by the carcinogen 7,12-Dimethylbenzathracene (DMBA) and short latency tumors (65 ± 11 days) induced by the progestin Medroxyprogesterone Acetate (MPA) plus DMBA in CD2F1 mice. Long latency tumors displayed a high frequency of <em>Pi3kca</em> and/or <em>Pten</em> mutations detected in 11 of 13 (85%) long latency cases (14/22, 64% overall). Eighty-two percent (9/11) of tumors carried the <em>Pik3ca</em> H1047L/R hot-spot mutation, as frequently found in human breast cancer. These tumors were luminal-like and mostly ER/PR+, as in humans. Transcriptome profiling indicated a significant activation of the PI3K-Akt pathway (p=3.82e-6). On the other hand MPA+DMBA induced short latency tumors displayed mutations in cancer drivers not commonly found mutated in human breast cancer (e.g. <em>Hras</em> and <em>Apc</em>). These tumors were mostly basal-like and MPA exposure led to <em>Rankl</em> overexpression (60 fold induction) and immunosuppressive gene expression signatures. In summary, long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas representing an excellent preclinical model for the testing of PIK3CA/Akt/mTOR pathway inhibitory therapies and a good platform for the developing of additional preclinical tools such as syngeneic transplants in immunocompetent hosts.en
dcterms.creator.authorAbba, Martín Carloses
dcterms.creator.authorZhong, Yies
dcterms.creator.authorLee, Jaehoes
dcterms.creator.authorKil, Hyunsukes
dcterms.creator.authorLu, Yuees
dcterms.creator.authorTakata, Yokoes
dcterms.creator.authorSimper, Melissa S.es
dcterms.creator.authorGaddis, Sallyes
dcterms.creator.authorShen, Jianjunes
dcterms.creator.authorAldaz, C. Marceloes
dcterms.extentp. 64289-64299es
dcterms.identifier.otherDOI 10.18632/oncotarget.11733es
dcterms.identifier.urlRecurso completoes
dcterms.isPartOf.issuevol. 7, no. 39es
dcterms.isPartOf.seriesOncotargetes
dcterms.issued2016-08
dcterms.languageIngléses
dcterms.licenseAttribution 4.0 International (BY 4.0)es
dcterms.publisherImpact Journalses
dcterms.subjectmammary tumorsen
dcterms.subjectDMBAen
dcterms.subjectMPAen
dcterms.subjectPik3caen
dcterms.subjectPtenen
dcterms.subject.materiaCiencias Médicases
Archivos
Paquete original
Mostrando1 - 1 de 1
Imagen en miniatura
Nombre:
11733-211137-1-PB.pdf-PDFA.pdf
Tamaño:
2.56 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo